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Adenoviruses (AdV) are emerging pathogens with a prevalence of 11% viruria and 6.5% viremia in kidney transplant recipients.
Although AdV infection is common, interstitial nephritis (ADVIN) is rare with only 13 biopsy proven cases reported in the
literature.We report a case of severeADVINwith characteristic histological features that includes severe necrotizing granulomatous
lesion with widespread tubular basement membrane rupture and hyperchromatic smudgy intranuclear inclusions in the tubular
epithelial cells.The patient was asymptomatic at presentation, and the high AdV viral load (quantitative PCR>2,000,000 copies/mL
in the urine and 646,642 copies/mL in the serum) confirmed the diagnosis.The patient showed excellent response to a combination
of immunosuppression reduction, intravenous cidofovir, and immunoglobulin therapy resulting in complete resolution of infection
and recovery of allograft function. Awareness of characteristic biopsy findings may help to clinch the diagnosis early which is
essential since the disseminated infection is associated with high mortality of 18% in kidney transplant recipients. Cidofovir is
considered the agent of choice for AdV infection in immunocompromised despite lack of randomized trials, and the addition of
intravenous immunoglobulin may aid in resolution of infection while help prevention of rejection.
1. Introduction
Adenoviruses (AdV) are emerging pathogens in solid organ
transplant recipients with clinical manifestation that ranges
from subclinical infection to fatal outcome. The reported
prevalence of AdV infection during the first year after kidney
transplant (KT) is 11% by urine culture and 6.5% by serum
PCR [1, 2]. Manifestations of urinary tract involvement
may include hemorrhagic cystitis, ureteral obstruction with
hydronephrosis, acute tubular necrosis, interstitial nephritis,
or a mass lesion in the kidney [3–5]. Adenovirus interstitial
nephritis (ADVIN) is rare in kidney transplant recipients
with 13 biopsy proven cases reported in the literature [6–
8]. We report a case of severe necrotizing ADVIN with
characteristic morphology on biopsy within three weeks after
kidney transplantation.
2. Case Report
2.1. Clinical History and Laboratory Data. A 44-year-old
African American male with end-stage renal disease from
hypertensive nephrosclerosis received a four-antigen mis-
match, flow crossmatch negative deceased donor kidney
transplantation.The patient received IL-2 receptor antagonist
(Basiliximab) for induction and tacrolimus, mycophenolate
mofetil (MMF), and prednisone for maintenance immuno-
suppression. The serological status for cytomegalovirus
(CMV) was donor positive/recipient negative, and the pati-
ent received trimethoprim-sulfamethoxazole and valganci-
clovir for infection prophylaxis. After the transplant, the
patient developed slow graft function (definition: serum cre-
atinine (SCr) >3.0mg/dL (265.2 𝜇mol/L) on day 5 with-
out requiring dialysis). Subsequently, allograft function
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Figure 1: Adenovirus tubulointerstitial nephritis. Light microscopy (H&E stain): (a) Severe diffuse interstitial inflammation, (Mag ×200).
(b) Granulomatous necrotizing lesions (black arrows). Inflammatory and tubular epithelial cell cast (white arrow) (Mag ×400). Electron
microscopy: (c) viral inclusion body in a tubular epithelial cell (×9,500). (d) Viral particles of varying densities (×80,000).
improved with SCr decreasing to 2.33mg/dL (205.97𝜇mol/L,
eGFR 38mL/min/1.73m2) on day 19. On subsequent fol-
lowup, SCr increased to 2.81mg/dL (248.40𝜇mol/L, eGFR
30mL/min/1.73m2) on day 22 and his urinalysis showed
persistentmicroscopic hematuria (RBC 10–100 cells/𝜇L) with
few atypical epithelial cells with no definite decoy cells.
Since the rise in SCr could not be attributed clinically to
volume status or tacrolimus toxicity (trough levels remained
between 8 and 10 ng/mL), allograft ultrasound and biopsy
were performed on day 24. The ultrasound showed an unex-
pected increase in echogenicity with poor corticomedullary
differentiation, but the perfusion and resistive indices (from
0.54 to 0.63) were normal.
2.2. Kidney Biopsy. Renal allograft biopsy showed a diffuse
severe inflammation consisting of mostly macrophages, neu-
trophils, and lymphocytes with few noncaseating granulo-
matous lesions (Figures 1(a) and 1(b)). The most unique
feature was the presence of extensive necrosis and basophilic
hyperchromatic smudgy intranuclear inclusion bodies in the
tubular epithelial cells (Figure 2). Additionally, there was
widespread tubular basement membrane disruption. The
tubulitis was minimal with no glomerular inflammation or
vasculitis. The immunostain for polyoma (BK virus) and
CMV were negative. The immunofluorescence (IF) for IgG,
IgA, IgM, C3, C1q, fibrinogen, kappa, and lambda in the
glomeruli, and C4d stain in the peritubular capillaries were
negative. Periodic acid Schiff and Jones stains were negative
for bacteria or fungi. Other routine investigations such
as blood and urine cultures, routine viral cultures, PCR
Figure 2: Adenovirus tubulointerstitial nephritis. Light microscopy
(H&E stain): renal allograft biopsy: shows severe diffuse necrotizing
granulomatous interstitial nephritis (white arrows). Basophilic,
smudgy nuclear inclusions in the tubular epithelial cells (black
arrow) (high power ×400).
assay for Epstein-Barr, and CMV and BK viauses were all
negative. Electron microscopy (EM) showed several foci of
viral particles of varying densities in the nuclei of tubular
epithelial cells (Figures 1(c) and 1(d)), but the crystalloid
aggregates were atypical for AdV. Because necrotizing gran-
ulomatous interstitial nephritis in the presence of smudgy
intranuclear viral inclusions is considered characteristic of
AdV, additional investigations such as immunohistochemical
(IHC) staining, in situ hybridization, and AdV quantitative
PCR in the serum and urine were requested. The IHC
stain and in situ hybridization for AdV were negative, but
the AdV real-time quantitative PCR (QPCR) assay showed
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Figure 3: Time line and clinical course after transplantation.
>2,000,000 copies/mL in the urine (normal <500 copies/mL,
Focus Diagnostics, MICROLAB, Cypress, CA, USA) and
646,642 copies/mL in the serum as shown in Figure 3. A
clinical diagnosis of ADVIN was confirmed based on high
viral load in the serum and urine with characteristicmorpho-
logical findings on the biopsy.
2.3. Diagnosis. Necrotizing adenovirus tubulo-interstitial
nephritis.
2.4. Clinical Followup. Subsequent to confirmation of AdV
interstitial nephritis, immunosuppression was minimized
significantly by discontinuation of MMF, reducing pred-
nisone to 5mg daily with a goal tacrolimus trough level
from 4 to 6 ng/mL. Despite reduction in immunosuppres-
sion, the hospital course was transiently complicated by
development of symptoms of intermittent fever, macroscopic
hematuria, diarrhea, and mild shortness of breath. The chest
X-ray showed bibasilar patchy opacities likely representing
pneumonia. Consequently, a reduced dose intravenous cid-
ofovir at 2.5mg/kg because of impaired allograft function
and intravenous immunoglobulin (IVIG) 500mg/kg was
initiated (Figure 3) for possible early dissemination. The
patient responded to therapy with resolution of all systemic
symptoms within a week. The patient received two addi-
tional doses of cidofovir biweekly which he tolerated with-
out adverse events including nephrotoxicity. Subsequently,
a vigilant increase in immunosuppression guided by AdV
quantitative PCR was initiated in order to prevent the poten-
tial for allograft rejection. The allograft function gradually
improved to a final SCr level of 1.53mg/dL (132.6 𝜇mol/L,
eGFR 63mL/min/1.73m2) during his followup. The time-
line of interventions, resolution of AdV infection, and the
improvement in allograft function are shown in Figure 3.
3. Discussion
Adenoviruses are nonenveloped double-stranded DNA
viruses that typically cause self-limiting respiratory and
gastrointestinal disease in immunocompetent individuals
[9]. Recently, AdV infection is increasingly recognized in
immunocompromised with high morbidity and mortality
[10]. The incidence of AdV infection ranges from 3% to 47%
in stem cell transplant recipients and from 5% to 22% in
solid organ transplant recipients [11, 12]. AdV infection is
commonly reported early after transplant when the immun-
osuppression is intense, and in one series 76% of all ADV
infection occurred within 3 months after KT [8, 13]. AdV
infection in transplant recipients may be a consequence of
a primary infection, reactivation of latent infection or
acquired through donor organs, and it is believed that
majority of the cases are due to reactivation of latent infe-
ction [14–17]. Disseminated infection can occur in severely
immunocompromised, and has been shown to be associated
with poor outcome with a mortality rate of 18% in KT
recipients [18].
Asymptomatic AdV infection is common, and the lack
of symptoms during viremia has been reported in 58% of
AdV infection in SOT recipients [2]. Hemorrhagic cystitis
and interstitial pneumonitis are the most common clini-
cal manifestations of AdV infection in kidney transplant
recipients [19]. Renal allograft involvement is rare and can
manifest as necrotizing tubulointerstitial nephritis and space-
occupying lesion with or without ureteral obstruction [5,
6]. The common differential diagnoses for ADVIN include
BK and CMV mediated interstitial nephritis for the most
part when viral inclusions are present. However, presence of
severe necrotizing granulomatous lesions with predominant
neutrophilic inflammation would be considered character-
istic for ADVIN [20, 21]. Additional features that are more
pronounced in AdV interstitial nephritis include presence of
mixed cellular infiltration, withmacrophages and histiocytes,
and tubular basement membrane disruption. Other differen-
tial diagnoses that should be considered for granulomatous
interstitial nephritis in the absence of viral inclusions include
drugs, anti-neutrophil cytoplasmic autoantibody associated
vasculitis, tuberculosis, sarcoidosis, and fungal infections.
Rarely, ADVIN and cellular rejection may coexist and pose
a diagnostic challenge. In such situations, presence of over-
riding tubulitis, vasculitis, and predominant T-lymphocyte
infiltration would favor presence of rejection [7].
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Multiple diagnostic modalities may be required to clinch
the diagnosis of ADVIN in cases where clinical suspicion
is high. Presence of white cell casts with decoy cells on
urinalysis may increase the suspicion for AdV infection.
Scanning electron microscopy of urinary sediment for viral
capsid and quantitative PCR for AdV DNA can confirm
presence of viruria. Although tissue diagnosis is ideal for
confirmation of ADVIN, not all PCR primers and antibodies
used for in situ hybridization and immunohistochemistry
provide complete coverage against at least 51 serotypes of
adenovirus. Culture for adenovirus usually becomes positive
in 2–7 days, but group D strains may take up to 4 weeks,
and group F strains (serotypes 40 and 41) may not grow
at all [22]. Additionally, because of the focal nature of the
disease in the kidney, IHC stain and in situ hybridization
may result in false negative tests. The diagnosis of ADVIN
can also be confirmed by AdV QPCR assay or by typical
electron microscopic finding of crystalline array particles
(70–80 nm) in tubular epithelium cells when characteristic
histopathological features are present in the biopsy [2, 23].
In contrast to the ADVIN case reported by Keddis et al.,
we were unable to confirm the presence of adenovirus in
the biopsy specimen by IHC or in situ hybridization despite
the characteristic morphology, presence of viral particles on
EM, and high viral load in the urine and serum. Conversely,
the EM did not show the viral particles in that case report,
whereas in our case, we were able to find the viral particle
on EM after extensive search [24]. These clinical scenarios
of inability to demonstrate the virus at times in the patho-
logical specimen are because of uncertainty of commercially
available antibodies to capture the genetic diversity of the
virus. These findings reiterate the caveats and interpretation
of the results and do not essentially exclude the diagnosis
when it is negative. In fact, the initial suspicion for ADVIN
in our case was based on the characteristic histopathological
findings.
The backbone of treatment for AdV infection in trans-
plant recipient is reduction of immunosuppression. Although
resolution of infection can occur with minimization of
immunosuppression alone, cidofovir, a cytosine nucleotide
analogue that inhibits DNA polymerase with greatest in
vitro activity against AdV, is considered the agent of choice
in immunocompromised despite the lack of randomized
trials [25, 26]. However, the side effect profile particularly
AKI and tubular dysfunction is a major concern that war-
rants consideration before its use. A less nephrotoxic new
lipid conjugate of cidofovir, Chimerix (CMX001), may be
of value in the future when available for commercial use
[27].
In summary, AdV is an infrequent cause of tubulointersti-
tial nephritis in KT recipients and should be considered in the
differential diagnosis of interstitial nephritis. Comprehension
of characteristic histopathological features of ADVIN, and
the caveats in its diagnosis as described in our case may
facilitate an early diagnosis and better outcome. Immuno-
suppression reduction in all and cidofovir therapy in selected
cases may significantly alter the outcome of AdV infection.
Serial assessment of viral load and lymphocyte recovery are
useful in monitoring the course of infection.
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